FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely oncology. The inventions may be used for a method of treating a tumour resistant to the VEGF antagonist therapy, as well as to a method of identifying a human individual carrying a tumour to be treated with the Bv8 antagonist. That is ensured by the effective amount of the Bv8 antagonist. The tumour is pre-treated with the vascular endothelium growth factor (VEGF) antagonist, while the Bv8 antagonist represents a Bv8 antibody or its fragment with specifying whether the individual is refractory to the VEGF antagonist therapy.
EFFECT: invention provides the effective treatment of the patients with the tumours resistant to the VEGF antagonists.
21 cl, 71 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| ANTI-BV8 ANTIBODIES AND USING THEM | 2010 |
|
RU2559542C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHOD FOR THEIR APPLICATION | 2013 |
|
RU2642319C2 |
| METHODS FOR TREATMENT OF TUMORS AND METASTASIS USING COMBINATION OF ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY | 2000 |
|
RU2236251C2 |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHOD FOR THEIR USE | 2013 |
|
RU2768282C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
